Repligen Corp (RGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN)

RGEN 146.04

-2.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (277)	9/16/2003 5:06:46 PM
From: VIXandMore	Read Replies (1) of 395

Repligen says court turns down protein patent LOS ANGELES, Sept 16 (Reuters) - Repligen Corp. (NasdaqNM:RGEN - News) on Tuesday said a U.S. District Court has ruled that there is not enough evidence to prove that the University of Michigan invented certain patents, licensed to Repligen, that cover a protein involved in the body's immune system. The company, based in Waltham, Massachusetts, said the ruling came in a lawsuit it filed against Bristol-Myers Squibb (NYSE:BMY - News) for correction of certain patents issued to Bristol for the protein, called CTLA4. Separately, Repligen said it received a notice of allowance from the U.S. Patent and Trademark Office on a patent claiming the use of CTLA4-Ig for treatment of rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosis. This patent is separate from the patents which are the subject of the court's ruling, the company said. CTLA4 is a T-cell regulatory protein which is one of the immune system's natural "off switches", which may have potential use in organ transplantation and autoimmune diseases.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next